Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 268

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 19
Chunk 268
---
 to ensure that it has sufficient liquidity available to meet its liabilities when due. The Company relies
on raising debt or equity financing in a timely manner.

The
following amounts are the contractual maturities of financial liabilities as of October 31, 2024 and 2023:

  October 31, 2024                              Total                   Within                   Within                 
                                                                        1 year                   2-5 years              
  Accounts payable and accrued liabilities      $          526,056      $           526,056      $              –       
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Due to related parties                                    48,962                   48,962                     –       
  Lease liability                                           53,142                   36,726                     16,416  
                                                $          628,160      $           611,744      $              16,416  

  October                                       Total                   Within                   Within     
  31, 2023                                                              1 year                   2-5 years  
  Accounts payable and accrued liabilities      $          617,004      $           617,004      $          
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Due to related parties                                    42,433                   42,433                 
                                                $          659,437      $           659,437      $          

F-33

CLEARMIND
MEDICINE INC.

Notes to
the Consolidated Financial Statements

(Expressed
in United States Dollars)

  13.      Capital     

The
Company manages its capital to maintain its ability to continue as a going concern and to provide returns to shareholders and benefits
to other stakeholders. The capital structure of the Company consists of cash and equity comprised of issued share capital and share premium,
warrants and share-based payment reserve.

The
Company manages its capital structure and makes adjustments to it in light of economic conditions. The Company, upon approval from its
Board, will balance its overall capital structure through new share issuances or by undertaking other activities as deemed appropriate
under the specific circumstances.

The
Company is not subject to externally imposed capital requirements and the Company’s overall strategy with respect to capital risk
management remains unchanged from the year ended October 31, 2024.

  14.      Commitments  

  On January 15, 2024, the Company entered into a license agreement with BIRAD, the research and development company of Bar